DMTTF - Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT | Benzinga
The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and their pharmaceutical compositions with exclusivity until 2041.
Considering the recently granted patent covering its clinically advanced compounds psilocybin analog CYB003 and DMT analog CYB004 as well as its announced intention to acquire U.K. short-acting psychedelics developer Small Pharma (OTCMKTS: DMTTF), Cybin rightly claims the new grant strengthens its forefront position within the development of "potential, best-in-class deuterated, tryptamine-based therapeutics for the treatment of mental health conditions.”
See Also: Treating ...